Hologic (NSDQ:HOLX) announced today that its revenues nearly doubled year-over-year in the first quarter of fiscal 2021. Marlborough, Mass.-based Hologic expects to report revenues of more than approximately $1.6 billion, an increase of 89.3% from the first quarter of 2020. That tops the company’s November guidance of between $1.35 billion and $1.425 billion for the quarter […]
Jefferies equity research reported that sales of transcatheter aortic valve replacement (TAVR) are better than the previous quarter with flat growth. Edwards Lifesciences (NYSE:EW) reported among its second-quarter results that TAVR sales had taken a -12% hit for the three months ended June 30, 2020. When the company reported its quarterly results, it noted that it […]
Jefferies Financial Group announced today that it is the first private-sector company to support a newly established public-private consortium launched by the U.S. Dept. of Health & Human Services (HHS). HHS launched the program last week, announcing that it joined with ApiJect Systems America to create a high-volume “surge” drug packaging solution in the U.S. by using […]
Senseonics (NYSE:SENS) posted a $200 million offering of common stock, preferred stock, debt securities and/or warrants, including an agreement for Jefferies to handle $50 million. The total offering includes the company’s common stock, which was trading at $1.03 per share in midday trading today. Senseonics — which makes glucose monitoring products — said the securities in […]
Palmaz Scientific, which filed for Chapter 11 bankruptcy protection last month, is reportedly embroiled in a dispute with Jefferies & Co. over its claim that the prominent investment bank was the placement agent for a funding round in 2012 and 2013. Co-founded by coronary stent pioneer Dr. Julio Palmaz in 2008, the San Antonio, Texas-based company […]
September 24, 2014 by Brad Perriello
A year after closing on a $30 million offering, Nanosphere said yesterday that it’s hired an investment bank to examine the proverbial "strategic alternatives," including a possible sale of the molecular diagnostics technology business.